Form 4 for ELDN Eledon Pharmaceuticals, Inc.
Accepted 2026-08-04 17:22:36 ET · period of report 2026-07-31 · accession 0001193125-26-333136 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-08-04 17:22 | 2026-07-31 | ELDN | Gros David-Alexandre C | CEO, Dir | A - Grant | $0.00 | +354.5K | 363.5K | +3,938% | $0 | |
| 2026-08-04 17:22 | 2026-07-31 | ELDN | Gros David-Alexandre C | CEO, Dir | F - Tax | $3.38 | -194.8K | 168.7K | -54% | -$658.4K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-07-31 | A | A | 354,454 | $0.00 | 363,454 | D | — | — | (F1) Represents shares issuable on settlement of a retention bonus award granted to the Reporting Person. The retention bonus agreement was entered into on April 27, 2023. |
| 2 | Common | Common Stock | 2026-07-31 | F | D | 194,791 | $3.38 | 168,663 | D | — | — | (F2) Represents shares withheld to pay tax withholding obligations due on the date of settlement. |